Label Value
DOI 10.1186/s12885-018-4223-y
TITLE Cost effectiveness analysis of afatinib versus pemetrexed-cisplatin for first-line treatment of locally advanced or metastatic EGFR mutation positive non-small-cell lung cancer from the Singapore healthcare payer’s perspective
TYPE article
Service Status Date Last Checked
Scopus Yes 2018-04-05T02:25:58.319794
Web of Science Yes 2018-04-26T03:01:20.455510
Compendex No 2020-10-15T18:54:58.530649